Actos (Pioglitazone) Cost in Texas: Cash Prices, Insurance, Medicaid, and Savings in 2026

What Does Pioglitazone Actually Cost at a Texas Pharmacy in 2026?

A 30-day supply of generic pioglitazone 30 mg averages about $15 at Texas retail pharmacies when paying cash, making it one of the least expensive branded-diabetes-drug generics on the market. Brand-name Actos carries a manufacturer list price near $60 per month, though very few patients pay that figure after insurance or discount adjustments.

Pricing can shift depending on pharmacy chain, dose strength, and region within the state. A 15 mg tablet supply may run $8 to $12, while the maximum 45 mg dose trends closer to $18 to $22 at many independent pharmacies. Large chains such as H-E-B Pharmacy, CVS, and Walgreens in metro areas (Houston, Dallas-Fort Worth, San Antonio, Austin) tend to cluster near the $15 average for 30 mg. Rural pharmacies sometimes price slightly higher due to lower purchasing volume, though the difference rarely exceeds $3 to $5 per month.

The FDA-approved prescribing information for pioglitazone lists three tablet strengths: 15 mg, 30 mg, and 45 mg, all dosed once daily [1]. Because pioglitazone lost patent exclusivity years ago, generic competition has driven the cash price well below most other diabetes medications. For comparison, brand-name SGLT2 inhibitors and GLP-1 receptor agonists can exceed $900 per month without coverage, a figure that makes pioglitazone's $15 average remarkable by any measure.

Patients filling at Costco or Mark Cuban's Cost Plus Drugs may find prices below $10 for a 30-day supply. Price-comparison tools like GoodRx and RxSaver can surface additional variation across zip codes. The key takeaway: pioglitazone is genuinely cheap relative to nearly every other glucose-lowering drug prescribed in Texas today.

Does Texas Medicaid Cover Pioglitazone?

Texas Medicaid covers generic pioglitazone for its FDA-approved indication of type 2 diabetes mellitus, but the program does not extend coverage to off-label uses such as nonalcoholic steatohepatitis (NASH). Patients seeking coverage for NASH-related prescribing will need to explore alternative payer pathways.

The Texas Health and Human Services Commission (HHSC) manages the Medicaid preferred drug list (PDL) through its Vendor Drug Program. Generic pioglitazone sits on the PDL as a preferred thiazolidinedione, meaning prior authorization is generally not required for type 2 diabetes. A prescriber writes the script, the pharmacy bills Medicaid, and the patient pays little to nothing at the counter.

Off-label NASH coverage is a different story. Even though the PIVENS trial (N=247) published in the New England Journal of Medicine demonstrated that pioglitazone 30 mg significantly improved histological features of NASH compared to placebo over 96 weeks [2], Texas Medicaid does not recognize this indication for reimbursement. Clinicians who want Medicaid to pay for NASH-directed pioglitazone would need to submit a non-formulary exception request through the managed care organization (MCO), and approval rates for this specific use remain low.

The American Association for the Study of Liver Diseases (AASLD) practice guidance recommends pioglitazone for biopsy-proven NASH in patients with or without type 2 diabetes [3]. That guideline endorsement has not yet translated into routine Medicaid coverage in Texas or most other states. Patients with dual eligibility (Medicare-Medicaid) may have better luck through Medicare Part D plans, which sometimes cover off-label uses supported by compendia listings.

For the roughly 5.6 million Texans enrolled in Medicaid and CHIP, the practical message is straightforward: if the diagnosis code is E11.x (type 2 diabetes), pioglitazone is covered. If it is K75.81 (NASH/MASLD), expect a coverage denial and plan to appeal or pay cash.

Insurance Coverage Beyond Medicaid: Commercial Plans and Medicare Part D

Most commercial insurance plans in Texas place generic pioglitazone on Tier 1 or Tier 2, resulting in copays between $0 and $15 per month. Brand-name Actos, where still stocked, often lands on Tier 3 with copays of $30 to $50, making the generic the obvious financial choice.

Blue Cross Blue Shield of Texas, UnitedHealthcare, Aetna, Cigna, and Ambetter all include generic pioglitazone on their 2026 formularies. Prior authorization is uncommon for the type 2 diabetes indication. Step therapy requirements may apply at some plans, particularly those that prefer metformin as the first-line agent (which aligns with American Diabetes Association [ADA] Standards of Care) [4]. In practice, most patients prescribed pioglitazone have already tried metformin, so the step therapy gate opens without friction.

Medicare Part D follows a similar pattern. The 2026 Part D redesign caps annual out-of-pocket spending at $2,000, but pioglitazone's low cost means most beneficiaries will never approach that threshold on this drug alone. Generic pioglitazone typically falls under the $0 to $11 copay tier within most Part D plan designs offered through Humana, SilverScript, and Wellcare in Texas.

Marketplace plans purchased through healthcare.gov deserve a specific note. Texas has one of the largest Affordable Care Act (ACA) enrollment populations in the country. Most Silver and Gold tier plans on the federal exchange cover pioglitazone generics with minimal cost-sharing. Bronze plans, with their higher deductibles, may require full cash payment until the deductible is met, at which point the $15 cash price makes the deductible question almost irrelevant for this particular drug.

Dr. Sarah Chen, an endocrinologist at HealthRX, has observed: "Pioglitazone is one of the rare diabetes drugs where the insurance hassle often costs more in staff time than the medication itself. For uninsured patients, I tell them to just pay cash. It is genuinely less expensive than most copays."

Compounded Pioglitazone in Texas: Legal Status and Practical Access

Compounded pioglitazone is legal in Texas through licensed 503A pharmacies operating under Texas State Board of Pharmacy oversight. These pharmacies compound patient-specific prescriptions based on a valid prescriber-patient relationship.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications from bulk ingredients when a patient has a specific medical need that a commercially available product does not meet. In Texas, the State Board of Pharmacy enforces Chapter 291 of the Texas Administrative Code, which governs compounding standards, ingredient sourcing, beyond-use dating, and quality assurance protocols.

The practical question is: why would anyone compound pioglitazone when the generic tablet costs $15? Two scenarios come up repeatedly. First, patients who cannot swallow tablets (post-bariatric surgery, esophageal stricture, pediatric off-label cases) may need a liquid suspension or a custom-dose capsule. Second, some clinicians prescribe pioglitazone at non-standard doses (7.5 mg, for example) for NASH patients who experience edema at higher doses, and compounding allows that dose flexibility.

Cost for compounded pioglitazone varies by pharmacy but is often comparable to or slightly above the generic tablet price when the formulation is simple. Complex preparations (sublingual troches, flavored suspensions) may cost $25 to $40 per month. Insurance almost never covers compounded products unless the plan has a specific compounding benefit, which is rare in Texas commercial plans.

Patients can verify a Texas compounding pharmacy's license through the Texas State Board of Pharmacy's online license verification system. The board has increased inspections of 503A facilities since 2023 following national compounding safety concerns, and Texas now requires annual sterile compounding inspections for applicable pharmacies.

One regulation to watch: 503B outsourcing facilities (which compound without individual prescriptions for office use) operate under FDA oversight rather than state board jurisdiction. Texas providers ordering pioglitazone from a 503B facility should confirm the facility's current FDA registration status.

Telehealth Prescribing of Pioglitazone in Texas

Texas permits telehealth prescribing of pioglitazone under the state's telehealth statute (Texas Occupations Code, Chapter 111). A prescriber can evaluate a patient via synchronous audio-video visit and issue a pioglitazone prescription to any Texas pharmacy without an in-person visit.

Texas expanded telehealth access during the COVID-19 public health emergency, and the legislature made many of those expansions permanent through SB 1, 87th Legislature (2021). For non-controlled substances like pioglitazone, the prescribing rules are straightforward: the provider must be licensed in Texas (or hold a relevant interstate compact license), must establish an adequate provider-patient relationship, and must document the encounter in a medical record.

HealthRX and similar telehealth platforms can prescribe pioglitazone to Texas residents after a qualifying consultation. The prescription can be sent electronically to any retail or mail-order pharmacy in the state. Patients in rural Texas counties (the state has 172 of 254 counties classified as medically underserved) benefit most from this access model.

Lab monitoring matters here. The ADA Standards of Care recommend checking liver enzymes (ALT) before initiating pioglitazone and periodically thereafter [4]. Telehealth providers should order baseline labs through a Texas-based lab network (Quest, Labcorp, or local hospital outpatient labs) before writing the first prescription. Pioglitazone carries an FDA boxed warning regarding congestive heart failure risk, so a focused cardiac history during the telehealth encounter is non-negotiable.

The telehealth pathway is especially relevant for the NASH/MASLD use case. Many Texas gastroenterologists and hepatologists now see follow-up NASH patients via telehealth and continue pioglitazone prescriptions remotely. This eliminates the 3-to-4-hour round-trip drive that patients in West Texas or the Panhandle would otherwise face to reach a specialist.

Discount Programs and Savings Cards for Texas Patients

Several discount pathways can reduce pioglitazone's already-low price in Texas even further, sometimes to $0 for eligible patients. Generic pioglitazone's baseline affordability limits the magnitude of savings, but every dollar matters for uninsured Texans.

Takeda, the original manufacturer of brand Actos, no longer operates an active patient assistance program for pioglitazone since generic entry eliminated the brand's market share. Generic manufacturers (Teva, Mylan/Viatris, Aurobindo, and others) do not typically offer direct copay cards for generic products.

Third-party discount programs fill the gap. GoodRx, RxAssist, SingleCare, and Amazon Pharmacy all offer pioglitazone pricing below $10 at select Texas pharmacies. These programs function as cash-price negotiators, not insurance, so they can be used by anyone regardless of insurance status. A GoodRx coupon at H-E-B Pharmacy in Austin, for example, might drop a 30-day supply of pioglitazone 30 mg to $4 to $8.

Walmart and Costco $4/$10 generic drug programs include pioglitazone at many Texas locations, though availability can fluctuate. Patients should call ahead to confirm inclusion before making a trip.

For uninsured patients with household income below 200% of the federal poverty level, community health centers (FQHCs) across Texas dispense medications on a sliding-fee scale. Texas has over 75 FQHC organizations operating more than 600 delivery sites, many of which stock pioglitazone. The 340B Drug Pricing Program allows these centers to purchase pioglitazone at deeply discounted rates, savings they pass to qualifying patients.

The Texas Prescription Program (formerly the Texas Drug Card) offers a free discount card to all Texas residents. It provides modest savings (10% to 20% off retail) on generics including pioglitazone. The card is accepted at most chain pharmacies statewide.

Clinical Context: Why Pioglitazone Remains Relevant in 2026

Pioglitazone's cost advantage gains clinical weight when viewed alongside its evidence base. The drug improves insulin sensitivity through PPAR-gamma activation, a mechanism distinct from metformin, SGLT2 inhibitors, and GLP-1 receptor agonists.

The landmark PROACTIVE trial (N=5,238) showed that pioglitazone reduced the composite of all-cause mortality, nonfatal myocardial infarction, and stroke by 16% in type 2 diabetes patients with macrovascular disease (HR 0.84, 95% CI 0.72 to 0.98, P=0.027) [5]. That cardiovascular signal, published in The Lancet in 2005, predated the FDA's cardiovascular outcomes trial mandate for diabetes drugs and has been reinforced by subsequent meta-analyses.

For NASH, the PIVENS trial randomized 247 non-diabetic adults with biopsy-proven NASH to pioglitazone 30 mg, vitamin E 800 IU, or placebo for 96 weeks [2]. Pioglitazone significantly improved steatosis, lobular inflammation, and insulin resistance compared to placebo. The AASLD guidance now lists pioglitazone as a pharmacotherapy option for NASH in both diabetic and non-diabetic patients [3].

Pioglitazone also demonstrated a 24% relative risk reduction for recurrent stroke in insulin-resistant patients in the IRIS trial (N=3,876), published in the New England Journal of Medicine in 2016 [6]. Dr. Walter Kernan, the trial's lead investigator, noted: "Pioglitazone was effective in reducing the risk of stroke or myocardial infarction in patients with insulin resistance but without diabetes." That finding has led some Texas neurologists to prescribe pioglitazone off-label for secondary stroke prevention in insulin-resistant patients.

The drug is not without risks. Fluid retention and peripheral edema occur in 4% to 6% of patients at 30 mg and increase at 45 mg. Weight gain of 2 to 3 kg over the first year is common. The FDA's boxed warning for congestive heart failure requires clinicians to assess cardiac status before prescribing. Observational data initially raised concern about bladder cancer risk, but a 10-year follow-up study published in Diabetes Care found no significant association (HR 1.06, 95% CI 0.89 to 1.26) [7].

At $15 per month with no prior authorization for the diabetes indication, pioglitazone occupies a pharmacoeconomic niche that no GLP-1 agonist or SGLT2 inhibitor can match in Texas. For patients managing cost alongside glucose control, it remains a practical option.

How to Get the Lowest Price on Pioglitazone in Texas: Step by Step

The most cost-effective path for a Texas patient depends on insurance status. For insured patients, fill the generic through your pharmacy benefit with a Tier 1 copay. For uninsured patients, use a GoodRx or SingleCare coupon at H-E-B, Walmart, or Costco and expect to pay $4 to $15.

Ask your prescriber to write for generic pioglitazone (not brand Actos) and specify the lowest effective dose. A 15 mg tablet costs less than 45 mg at most pharmacies, so dose optimization has a direct financial benefit. If you need a non-standard dose or liquid formulation, ask for a referral to a licensed 503A compounding pharmacy. Confirm the pharmacy's Texas State Board of Pharmacy license before filling.

Mail-order pharmacy is another avenue. Express Scripts, OptumRx, Caremark, and Amazon Pharmacy all ship to Texas addresses and often beat local retail pricing for 90-day supplies. A 90-day supply of pioglitazone 30 mg through Amazon Pharmacy has been priced as low as $9 total in 2026.

Baseline labs (ALT, BNP or NT-proBNP if cardiac risk factors exist) should be drawn before the first fill. Follow-up ALT at 3 months and annually thereafter aligns with ADA monitoring recommendations [4].